EP1853230A2 — Dosage form and method for sustained release of a substituted pyrazine compound
Assigned to Jazz Pharmaceuticals Inc · Expires 2007-11-14 · 19y expired
What this patent protects
The invention is directed to a dosage form and method for administering a therapeutic agent in a sustained release manner to provide an intended therapeutic effect while minimizing the side effects associated with the therapeutic agent. The therapeutic agent is selected from a gr…
USPTO Abstract
The invention is directed to a dosage form and method for administering a therapeutic agent in a sustained release manner to provide an intended therapeutic effect while minimizing the side effects associated with the therapeutic agent. The therapeutic agent is selected from a group of substituted pyrazine compounds and may be (3)-(2,3,5-trichloro-phenyl)-pyrazine-(2,6)-diamine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.